Validated high throughput microneutralization assay for anti-AAV2 neutralizing antibodies (NAbs) in clinical trials in support of gene therapy 2247247
Recombinant adeno-associated (AAV) viral vectors are being widely used in gene therapy. One of the challenges for AAV-based therapy is the presence of pre-existing neutralizing antibodies (NAbs) that humans develop against AAV throughout life. These NAbs inhibit the binding of viral vector to the cells resulting...